Operating margin
−226.0% Fiscal year 2025
No rank: too few peers or not computed yet.
Operating income divided by revenue: what the core business earns before interest and taxes.
About the company
ImmunityBio, based in California, develops immunotherapies against cancer and infectious diseases. Its drug Anktiva is approved in the US for a form of bladder cancer. Further drug candidates are being tested in trials. As of Oct 16, 2026
Fact sheet (from the annual report) Biotechnology and vaccines · San Diego, USA
ImmunityBio is a biotech company that develops and markets immunotherapies against cancer and infectious diseases. Its main product, ANKTIVA, is a fusion protein that activates NK cells and several types of T cells. In the United States, ANKTIVA has been approved since April 2024 with BCG for adults with BCG-unresponsive non-muscle-invasive bladder cancer (carcinoma in situ). There are also approvals in the UK and the Kingdom of Saudi Arabia and, since February 2026, a conditional approval in the European Union. The company is testing ANKTIVA together with standard therapies in other tumor types, for example in lung and pancreatic cancer. For distribution in the European Union and the Middle East, it works with partners such as Accord Healthcare and Cigalah.
Automatically summarized from SEC annual report (10-K, filed Feb 23, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 17, 2026
Price performance at a glance
Last 30 trading days
- Today +10.5%
- 7 days −1.6%
- 30 days +2.3%
- 1 year +224.4%
Day range (last trading day)
−10.0%Price at 94% of the range+0.6%
52-week range
−77.4%Price at 64% of the range+44.0%
- Distance from the all-time high
- −81.0%
Our own calculation from the exchange’s daily candles, as of Oct 27, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
Pullback in trend · Analysis method
This method currently detects no pattern for IBRX. The check runs daily after the close.
You see new patterns immediately from Watcher, on the free plan 2 days after they form. Plans and pricing
What does the pattern show?
What is this? In an intact uptrend (price above the 200-day line, 50-day line rising), the price pulls back to the 50-day line after a rise and closes back above it.
This is a calculated analysis, not a forecast and not a call to buy. Risk notice and investment advice
Fundamental analysis
SEC filing (10-K, 10-Q)Required reports of listed companies to the US Securities and Exchange Commission (SEC): 10-K is the annual report, 10-Q the quarterly report, 20-F the annual report of foreign companies. We show the figures of the first filing.Example: 10-K for the fiscal year ending Sep 27, 2025, filed on Oct 31, 2025.More in the Academy: Lesson revenue, profit and marginImmunityBio · Sector Health Care · amounts in USD
Information only – does not affect the other analysis methods, not investment advice. Source: SEC filings, As of Feb 23, 2026.
Quality checks
Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.
Fiscal year to Dec 31, 2025
Quality
Profitability, consistency, balance sheet · 2 without data
0 of 6 criteria met
Growth
Revenue and earnings per share · 3 without data
4 of 4 criteria met
Dividend
Level, consistency, coverage · 6 without data
0 of 1 criteria met
Financial strength
Piotroski, debt, liquidity · 1 without data
1 of 5 criteria met
Quality 0 of 6 met · 2 without data
- no data: Gross margin above 40% not stated in the SEC filings
- not met: Operating margin above 15% −226.0%
- not met: Net margin above 10% −310.2%
- no data: Return on equity above 15% negative equity
- not met: Free cash flow margin above 10% −272.6%
- not met: Profit in each of the last 5 fiscal years 0 of 5
- not met: Free cash flow positive in each of the last 3 fiscal years 0 of 3
- not met: Equity ratio above 30% −99.7%
Net margin
−310.2% Fiscal year 2025
No rank: too few peers or not computed yet.
Profit after all costs, interest and taxes divided by revenue.
Return on assets
−70.0% Fiscal year 2025 (total assets at year end)
No rank: too few peers or not computed yet.
Net income divided by total assets at fiscal year end.
Equity ratio
−99.7% Fiscal year 2025
No rank: too few peers or not computed yet.
Equity as a share of total assets. Usually low for banks.
Free cash flow margin
−272.6% Fiscal year 2025
No rank: too few peers or not computed yet.
Free cash flow divided by revenue.
Free cash flow
−308.8M USD Fiscal year 2025
Operating cash flow minus capital expenditure on property and equipment.
Growth 4 of 4 met · 3 without data
- met: Over 3 years, revenue grew by more than 5% per year +678.6%
- met: Over 5 years, revenue grew by more than 5% per year +299.7%
- met: Over 10 years, revenue grew by more than 5% per year +85.4%
- no data: Over 3 years, EPS grew by more than 5% per year not computable (loss in the first or last year, or figures missing)
- no data: Over 5 years, EPS grew by more than 5% per year not computable (loss in the first or last year, or figures missing)
- no data: Revenue rose in at least 4 of the last 5 fiscal years fewer than 6 fiscal years reported
- met: Revenue rose in the last fiscal year +668.3%
Revenue growth 3 years
+678.6% per year
No rank: too few peers or not computed yet.
Average growth per year over 3 fiscal years.
Revenue growth 5 years
+299.7% per year
No rank: too few peers or not computed yet.
Average growth per year over 5 fiscal years.
Revenue growth 10 years
+85.4% per year
No rank: too few peers or not computed yet.
Average growth per year over 10 fiscal years.
Dividend 0 of 1 met · 6 without data
- not met: Pays a dividend no dividend per share reported for the last fiscal year
- no data: Payout ratio at most 60% of earnings pays no dividend
- no data: Dividend paid in each of the last 5 fiscal years pays no dividend
- no data: Dividend per share never lowered in the last 5 fiscal years pays no dividend
- no data: Dividend per share higher than 5 years ago pays no dividend
- no data: Free cash flow per share covers the dividend pays no dividend
- no data: Dividends paid over the last 5 years covered by free cash flow pays no dividend
Financial strength 1 of 5 met · 1 without data
- not met: Piotroski F-Score at least 7 of 9 3 of 7 · 2 without data
- not met: Long-term debt no higher than equity negative equity
- met: Current assets cover current liabilities 5.10
- not met: Positive equity −500.5M USD
- no data: In 5 years, share count up by at most 5% no comparable share count 5 years ago
- not met: Free cash flow positive in the last fiscal year −308.8M USD
Piotroski F-Score
3 of 7 Fiscal year 2025
No rank: not all 9 criteria have data.
Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.
Debt / equity
negative equity at fiscal year end
No rank: too few peers or not computed yet.
Long-term financial debt divided by equity.
Liquidity (current ratio)
5.10 at fiscal year end
No rank: too few peers or not computed yet.
Current assets divided by current liabilities.
Change in share count
+130.0% in 3 years
No rank: too few peers or not computed yet.
Change in diluted share count. Negative = share buybacks, positive = new shares.
The 9 criteria of the Piotroski F-Score
- not met: Profit in the last fiscal year (positive return on assets)
- not met: Positive operating cash flow
- not met: Return on assets higher than the prior year
- met: Operating cash flow higher than net income
- no data: Long-term debt relative to total assets fell
- met: Liquidity (current assets / current liabilities) rose
- not met: No additional shares (diluted share count did not rise)
- no data: Gross margin higher than the prior year
- met: Revenue relative to total assets higher than the prior year
Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.
Price-based criteria (P/E, dividend yield) are shown to signed-in users.
Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock.
In short
- Light green: Revenue grew over 5 years (+299.7% per year), at least as fast as the sector median.
- Light red: Loss in the last fiscal year.
- Light red: Profit in 0 of 10 fiscal years.
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
- Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 44.0K USD · Net income −120.8M USD · Net margin −274,565.9%
- Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 45.0K USD · Net income −96.4M USD · Net margin −214,273.3%
- Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 47.0K USD · Net income −96.2M USD · Net margin −204,736.2%
- Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 43.0K USD · Net income −65.8M USD · Net margin −152,997.7%
- Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 111.0K USD · Net income −92.4M USD · Net margin −83,227.9%
- Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 934.0K USD · Net income −346.8M USD · Net margin −37,129.6%
- Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 240.0K USD · Net income −416.6M USD · Net margin −173,569.6%
- Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 622.0K USD · Net income −583.2M USD · Net margin −93,761.4%
- Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 14.7M USD · Net income −413.6M USD · Net margin −2,804.8%
- Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 113.3M USD · Net income −351.4M USD · Net margin −310.2%
- Quarter Q3/23 (Jul 1, 2023 – Sep 30, 2023): Revenue 82.0K USD · Net income −95.6M USD · Net margin −116,563.4%
- Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Revenue 139.0K USD · Net income −233.4M USD · Net margin −167,907.9% · Q4 derived (year minus 9 months), may be distorted by restatements
- Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Revenue 40.0K USD · Net income −134.1M USD · Net margin −335,272.5%
- Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Revenue 1.0M USD · Net income −134.6M USD · Net margin −12,852.3%
- Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Revenue 6.1M USD · Net income −85.7M USD · Net margin −1,404.0%
- Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Revenue 7.6M USD · Net income −59.2M USD · Net margin −783.4% · Q4 derived (year minus 9 months), may be distorted by restatements
- Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Revenue 16.5M USD · Net income −129.6M USD · Net margin −784.9%
- Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Revenue 26.4M USD · Net income −92.6M USD · Net margin −350.3%
- Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Revenue 32.1M USD · Net income −67.3M USD · Net margin −209.8%
- Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Revenue 38.3M USD · Net income −61.9M USD · Net margin −161.8% · Q4 derived (year minus 9 months), may be distorted by restatements
- Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Revenue 44.2M USD · Net income −632.8M USD · Net margin −1,431.4%
- Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Revenue 51.2M USD · Net income −230.4M USD · Net margin −449.6%
- Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Earnings per share not available
- Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Earnings per share not available
- Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Earnings per share not available
- Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Earnings per share −0.43 USD
- Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Earnings per share −0.59 USD
- Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Earnings per share −0.89 USD
- Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Earnings per share −1.04 USD
- Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Earnings per share −1.15 USD
- Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Earnings per share −0.62 USD
- Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Earnings per share −0.38 USD
- Quarter Q3/23 (Jul 1, 2023 – Sep 30, 2023): Earnings per share −0.19 USD
- Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Earnings per share not reported separately for Q4
- Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Earnings per share −0.20 USD
- Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Earnings per share −0.20 USD
- Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Earnings per share −0.14 USD
- Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Earnings per share not reported separately for Q4
- Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Earnings per share −0.15 USD
- Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Earnings per share −0.10 USD
- Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Earnings per share −0.07 USD
- Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Earnings per share not reported separately for Q4
- Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Earnings per share −0.62 USD
- Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Earnings per share −0.22 USD
No reported values for “Dividend per share” in this interval.
No reported values for “Dividend per share” in this interval.
Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 113.3M USD · Net income −351.4M USD · Net margin −310.2%
Figures over time
Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.
Money flow in fiscal year 2025
Of 100 USD of revenue, no profit was left.
Operating loss: −226.0% of revenue
Money flow as a table
| Item | Amount | of revenue |
|---|---|---|
| Revenue | 113.3M USD | 100.0% |
| Cost of revenue and operating expenses | 369.3M USD | 326.0% |
Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.
Returns
Return on equity fell in 4 years from −41.2% to −78.7%.
Return on equityReturn on assets- Fiscal year 2016: Return on equity −41.2% · Return on assets −38.1%
- Fiscal year 2017: Return on equity −44.1% · Return on assets −38.5%
- Fiscal year 2018: Return on equity −65.9% · Return on assets −52.9%
- Fiscal year 2019: Return on equity −54.5% · Return on assets −46.0%
- Fiscal year 2020: Return on equity −78.7% · Return on assets −60.8%
- Fiscal year 2021: Return on equity not available · Return on assets −74.0%
- Fiscal year 2022: Return on equity not available · Return on assets −115.0%
- Fiscal year 2023: Return on equity not available · Return on assets −115.6%
- Fiscal year 2024: Return on equity not available · Return on assets −108.0%
- Fiscal year 2025: Return on equity not available · Return on assets −70.0%
Equity and long-term debt
The equity ratio fell in 5 years from 77.3% to −99.7%.
EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases. Definition changes: some years use a different debt tag.- Fiscal year 2016: Equity 293.4M USD · Long-term debt not available
- Fiscal year 2017: Equity 218.8M USD · Long-term debt not available
- Fiscal year 2018: Equity 146.0M USD · Long-term debt not available
- Fiscal year 2019: Equity 120.7M USD · Long-term debt 757.0K USD
- Fiscal year 2020: Equity 117.4M USD · Long-term debt 1.4M USD
- Fiscal year 2021: Equity −242.2M USD · Long-term debt not available
- Fiscal year 2022: Equity −447.3M USD · Long-term debt 241.3M USD
- Fiscal year 2023: Equity −587.0M USD · Long-term debt 577.0M USD
- Fiscal year 2024: Equity −489.1M USD · Long-term debt 0.0 USD
- Fiscal year 2025: Equity −500.5M USD · Long-term debt not available
Liquidity (current ratio)
The current ratio rose in 5 years from 3.06 to 5.10.
Current ratio- Fiscal year 2016: Current ratio 16.34
- Fiscal year 2017: Current ratio 6.35
- Fiscal year 2018: Current ratio 3.26
- Fiscal year 2019: Current ratio 4.82
- Fiscal year 2020: Current ratio 3.06
- Fiscal year 2021: Current ratio 0.91
- Fiscal year 2022: Current ratio 0.28
- Fiscal year 2023: Current ratio 5.05
- Fiscal year 2024: Current ratio 3.36
- Fiscal year 2025: Current ratio 5.10
Cash flow
Free cash flow fell in 5 years from −73.1M USD to −308.8M USD.
Operating cash flowCapital expenditureFree cash flow in USD- Fiscal year 2016: Operating cash flow −38.6M USD · Capital expenditure 6.6M USD · Free cash flow −45.2M USD
- Fiscal year 2017: Operating cash flow −48.8M USD · Capital expenditure 34.8M USD · Free cash flow −83.6M USD
- Fiscal year 2018: Operating cash flow −63.4M USD · Capital expenditure 13.1M USD · Free cash flow −76.5M USD
- Fiscal year 2019: Operating cash flow −61.4M USD · Capital expenditure 4.2M USD · Free cash flow −65.5M USD
- Fiscal year 2020: Operating cash flow −70.5M USD · Capital expenditure 2.6M USD · Free cash flow −73.1M USD
- Fiscal year 2021: Operating cash flow −274.4M USD · Capital expenditure 33.6M USD · Free cash flow −308.0M USD
- Fiscal year 2022: Operating cash flow −337.5M USD · Capital expenditure 78.2M USD · Free cash flow −415.7M USD
- Fiscal year 2023: Operating cash flow −366.8M USD · Capital expenditure 30.6M USD · Free cash flow −397.3M USD
- Fiscal year 2024: Operating cash flow −391.2M USD · Capital expenditure 6.9M USD · Free cash flow −398.1M USD
- Fiscal year 2025: Operating cash flow −304.9M USD · Capital expenditure 3.8M USD · Free cash flow −308.8M USD
Share count
The share count rose in 4 years by 136.3% – more new shares were issued than repurchased (dilution).
Diluted share count- Fiscal year 2016: Diluted share count not available
- Fiscal year 2017: Diluted share count not available
- Fiscal year 2018: Diluted share count not available
- Fiscal year 2019: Diluted share count not available
- Fiscal year 2020: Diluted share count not available
- Fiscal year 2021: Diluted share count 389.2M
- Fiscal year 2022: Diluted share count 399.9M
- Fiscal year 2023: Diluted share count 508.6M
- Fiscal year 2024: Diluted share count 700.4M
- Fiscal year 2025: Diluted share count 919.9M
From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.
Dividends and share repurchases
How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.
- Dividend per share
- none pays no dividend
Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.
Valuation over time
Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users. Log in
Key figures with traffic lights
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
Revenue growth
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth+299.7% per year, last 5 years
Sector Health Care: median +7.8% (60 symbols)
What does this mean? Revenue: over 5 years it grew by 299.7% per year on average – at least as fast as the median company in the sector (+7.8%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net income (total)
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth– per year, last 5 years
Sector Health Care: median +7.5% (46 symbols)
per share: not computable (loss in the first or last year)
What does this mean? There was a loss in the first or last year. An annual growth rate cannot be calculated meaningfully then.
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net margin
Profit marginThe share of revenue that is left as profit after all costs.Example: Profit €60m on €500m revenue → margin 12%.More in the Academy: Lesson revenue, profit and margin−310.2% last fiscal year
Sector Health Care: median 12.9% (63 symbols)
What does this mean? Of every 100 USD in revenue there was no profit but a loss of 310.18 USD. Five years ago the margin was −83,227.9%.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
Debt / equity
Debt-to-equity ratioFinancial debt (loans, bonds) divided by equity. A high value amplifies good and bad years alike. The key figures bar in the chart only uses long-term financial debt.Example: Financial debt €300m, equity €500m → 0.6.More in the Academy: Lesson debt, dividends and growth– latest balance sheet
Sector Health Care: median 0.66 (40 symbols)
What does this mean? Equity is negative (e.g. due to share buybacks). A debt-to-equity ratio cannot be formed meaningfully then.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
Payout ratio
Payout ratioThe share of profit that a company pays out as a dividend. Above 100% it pays out more than it earns.Example: Dividend €1, earnings per share €2.50 → payout ratio 40%.More in the Academy: Lesson debt, dividends and growth– Dividend / earnings per share
Sector Health Care: median 28% (31 symbols)
What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
Profitable years
Profitable yearsHow many of the last fiscal years ended with a profit rather than a loss on the bottom line. The figure shows how consistently a company earns.Example: Profit in 9 of 10 years → one loss year.More in the Academy: Lesson revenue, profit and margin0 of 10 fiscal years with a profit
What does this mean? In 0 of the last 10 fiscal years the bottom line showed a profit. 10 years ended with a loss.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
All figures as a table
| Year | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| 2025 | Dec 31, 2025 | 113.3M | −351.4M | −310.2% | −0.38 | – | – |
| 2024 | Dec 31, 2024 | 14.7M | −413.6M | −2,804.8% | −0.62 | – | – |
| 2023 | Dec 31, 2023 | 622.0K | −583.2M | −93,761.4% | −1.15 | – | – |
| 2022 | Dec 31, 2022 | 240.0K | −416.6M | −173,569.6% | −1.04 | – | – |
| 2021 | Dec 31, 2021 | 934.0K | −346.8M | −37,129.6% | −0.89 | – | – |
| 2020 | Dec 31, 2020 | 111.0K | −92.4M | −83,227.9% | −0.59 | – | – |
| 2019 | Dec 31, 2019 | 43.0K | −65.8M | −152,997.7% | −0.43 | – | – |
| 2018 | Dec 31, 2018 | 47.0K | −96.2M | −204,736.2% | – | – | – |
| 2017 | Dec 31, 2017 | 45.0K | −96.4M | −214,273.3% | – | – | – |
| 2016 | Dec 31, 2016 | 44.0K | −120.8M | −274,565.9% | – | – | – |
| Quarter | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| Q2/26 | Jun 30, 2026 | 51.2M | −230.4M | −449.6% | −0.22 | – | – |
| Q1/26 | Mar 31, 2026 | 44.2M | −632.8M | −1,431.4% | −0.62 | – | – |
| Q4/25* | Dec 31, 2025 | 38.3M | −61.9M | −161.8% | – | – | – |
| Q3/25 | Sep 30, 2025 | 32.1M | −67.3M | −209.8% | −0.07 | – | – |
| Q2/25 | Jun 30, 2025 | 26.4M | −92.6M | −350.3% | −0.10 | – | – |
| Q1/25 | Mar 31, 2025 | 16.5M | −129.6M | −784.9% | −0.15 | – | – |
| Q4/24* | Dec 31, 2024 | 7.6M | −59.2M | −783.4% | – | – | – |
| Q3/24 | Sep 30, 2024 | 6.1M | −85.7M | −1,404.0% | −0.14 | – | – |
| Q2/24 | Jun 30, 2024 | 1.0M | −134.6M | −12,852.3% | −0.20 | – | – |
| Q1/24 | Mar 31, 2024 | 40.0K | −134.1M | −335,272.5% | −0.20 | – | – |
| Q4/23* | Dec 31, 2023 | 139.0K | −233.4M | −167,907.9% | – | – | – |
| Q3/23 | Sep 30, 2023 | 82.0K | −95.6M | −116,563.4% | −0.19 | – | – |
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.
Insiders
Insider transactionsExecutives, directors and major shareholders (over 10%) of US companies report their own transactions in their company’s stock to the SEC within two business days (Form 4). Purchases in the market count as more meaningful than sales (often taxes, estate planning).Example: Three executives acquire stock worth a total of 2 million USD within two weeks → “purchases by several insiders”.More in the Academy: Glossary| Period | Purchases | Sales | Net |
|---|---|---|---|
| 3 months | $00 people | $1.1M2 people | −$1.1M |
| 6 months | $00 people | $5.0M3 people | −$5.0M |
| 12 months | $00 people | $9.5M3 people | −$9.5M |
Latest transactions
- Oct 5, 2026 Simon Barry J. Director Open-market sale · 10b5-1 plan 25,000 shares · $268.8K · SEC
- Oct 2, 2026 Cohen Cheryl Director Open-market sale · 10b5-1 plan 81,056 shares · $851.1K · SEC
- Jul 2, 2026 Cohen Cheryl Director Open-market sale · 10b5-1 plan 131,210 shares · $1.2M · SEC
- Jul 1, 2026 Selecky Christobel Director Open-market sale · 10b5-1 plan 159,478 shares · $1.4M · SEC
- Jun 30, 2026 Selecky Christobel Director Open-market sale · 10b5-1 plan 1,000 shares · $9.0K · SEC
- Jun 29, 2026 Selecky Christobel Director Open-market sale · 10b5-1 plan 95,722 shares · $862.2K · SEC
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
Trend score +30
Price vs. EMA 50-15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)-15
Highs and lows+10
Relative strength+15
Volatility and trend strength
ADX 14 (trend strength)26.6
Rel. strength 60 d+19.5%
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.
More stocks from Health Care
News
Latest news
Jim Cramer Calls Celsius 'A Second-Rate Monster,' Says Stick With the Original Finnhub · Benzinga · Oct 27, 09:31
IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover Wave Yahoo Finance · Oct 27, 08:14
IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover Wave Finnhub · Yahoo · Oct 27, 08:14
Is HeartSciences Inc. (HSCS) Stock Outpacing Its Medical Peers This Year? Yahoo Finance · Oct 22, 14:40
Is HeartSciences Inc. (HSCS) Stock Outpacing Its Medical Peers This Year? Finnhub · Yahoo · Oct 22, 14:40
ImmunityBio Locks Anktiva Trial Database, Eyes November Results As FDA Filing Nears Yahoo Finance · Oct 21, 15:35
ImmunityBio Locks Anktiva Trial Database, Eyes November Results As FDA Filing Nears Finnhub · Yahoo · Oct 21, 15:35
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer Yahoo Finance · Oct 21, 13:30
Posts
No posts on IBRX yet – log in to join the discussion.
Posts are opinions of users and only visible after logging in. Community rules